Pharmacogenetics in major depression: A comprehensive meta-analysis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 183-194

  Niitsu, Tomihisa ^a,b   Fabbri, Chiara ^a   Bentini, Francesco ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antidepressant; Major depressive disorder; Meta analysis; Polymorphism; Remission; Response

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

5 HTTLPR GENE; ABCB1 GENE; ARTICLE; ASIAN; BDNF GENE; CAUCASIAN; COMT GENE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; ETHNICITY; FKBP5 GENE; GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; GNB3 GENE; HETEROZYGOTE; HTR1A GENE; HTR2A GENE; HTR6 GENE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PHARMACOGENETICS; RANDOM EFFECT MODEL; SLC6A2 GENE; STATISTICAL MODEL; STIN2 SLC6A4 GENE; SYSTEMATIC REVIEW; TPH1 GENE;

AD(S); ANTIDEPRESSANT; ANTIDEPRESSANT(S); GENDEP; GENOME-BASED THERAPEUTIC DRUGS FOR DEPRESSION; GENOME-WIDE ASSOCIATION STUDY; GWAS; LD; LINKAGE DISEQUILIBRIUM; MAJOR DEPRESSION; MAJOR DEPRESSIVE DISORDER; MARS; MD; MDD; META-ANALYSIS; MUNICH ANTIDEPRESSANT RESPONSE SIGNATURE PROJECT; POLYMORPHISM; REMISSION; RESPONSE; SEQUENCED TREATMENT ALTERNATIVES TO RELIEVE DEPRESSION; STAR*D;

ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, GENETIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 84879472437     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.05.011     Document Type: Article

References (147)

1. Alexopoulos G.S., Glatt C.E., Hoptman M.J., Kanellopoulos D., Murphy C.F., Kelly R.E., et al. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J. Affect. Disord. 2010, 125:262-268.
2. Arias B., Catalan R., Gasto C., Gutierrez B., Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J. Psychopharmacol. (Oxf.,) 2005, 19:166-172.
3. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 2006, 90:251-256.
4. Baffa A., Hohoff C., Baune B.T., Muller-Tidow C., Tidow N., Freitag C., et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010, 62:121-131.
5. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry 2008, 13:544-556.
6. Baum A.E., Hamshere M., Green E., Cichon S., Rietschel M., Noethen M.M., et al. Meta-analysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol. Psychiatry 2008, 13:466-467.
7. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
8. Baune B.T., Hohoff C., Roehrs T., Deckert J., Arolt V., Domschke K. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?. Neurosci. Lett. 2008, 436:111-115.
9. Benedetti F., Colombo C., Pirovano A., Marino E., Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacol. 2009, 203:155-160.
10. Benedetti F., Dallaspezia S., Colombo C., Lorenzi C., Pirovano A., Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry 2010, 25:476-478.
11. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
12. Binder E.B. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009, 34(Suppl. 1):S186-S195.
13. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
14. Bosch O.G., Seifritz E., Wetter T.C. Stress-related depression: neuroendocrine, genetic, and therapeutical aspects. World J. Biol. Psychiatry 2012, 13:556-568.
15. Bozina N., Peles A.M., Sagud M., Bilusic H., Jakovljevic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J. Biol. Psychiatry 2008, 9:190-197.
16. Brent D., Melhem N., Ferrell R., Emslie G., Wagner K.D., Ryan N., et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 2010, 167:190-197.
17. Bukh J.D., Bock C., Vinberg M., Werge T., Gether U., Vedel Kessing L. Interaction between genetic polymorphisms and stressful life events in first episode depression. J. Affect. Disord. 2009, 119:107-115.
18. Bukh J.D., Bock C., Vinberg M., Werge T., Gether U., Kessing L.V. No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur. Neuropsychopharmacol. 2010, 20:327-335.
19. Calati R., Gaspar-Barba E., Yukler A., Serretti A. T3111C clock single nucleotide polymorphism and mood disorders: a meta-analysis. Chronobiol. Int. 2010, 27:706-721.
20. Chi M.H., Chang H.H., Lee S.Y., Lee I.H., Gean P.W., Yang Y.K., et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J. Affect. Disord. 2010, 126:430-435.
21. Choi M.J., Kang R.H., Ham B.J., Jeong H.Y., Lee M.S. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005, 52:155-162.
22. Choi M.J., Kang R.H., Lim S.W., Oh K.S., Lee M.S. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006, 1118:176-182.
23. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:695-698.
24. Cusin C., Serretti A., Zanardi R., Lattuada E., Rossini D., Lilli R., et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. neuropsychopharmacol./Off.Sci. J. Coll. Int. Neuropsychopharmacol. (CINP). 2002, 5:27-35.
25. Dogan O., Yuksel N., Ergun M.A., Yilmaz A., Ilhan M.N., Karslioglu H.E., et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test. 2008, 12:225-231.
26. Domschke K., Lawford B., Laje G., Berger K., Young R., Morris P., et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol.(CINP). 2010, 13:93-101.
27. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
28. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
29. Franchini L., Serretti A., Gasperini M., Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J. Psychiatr. Res. 1998, 32:255-259.
30. Gex-Fabry M., Eap C.B., Oneda B., Gervasoni N., Aubry J.M., Bondolfi G., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit. 2008, 30:474-482.
31. Govindarajan A., Rao B.S., Nair D., Trinh M., Mawjee N., Tonegawa S., et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13208-13213.
32. Gudayol-Ferre E., Herrera-Guzman I., Camarena B., Cortes-Penagos C., Herrera-Abarca J.E., Martinez-Medina P., et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J. Affect. Disord. 2010, 127:343-351.
33. Ham B.J., Lee M.S., Lee H.J., Kang R.H., Han C.S., Choi M.J., et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr. Genet. 2005, 15:299-301.
34. Ham B.J., Lee B.C., Paik J.W., Kang R.H., Choi M.J., Choi I.G., et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:104-107.
35. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin. Neurosci. 2010, 64:341-357.
36. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
37. Hong C.J., Chen T.J., Yu Y.W., Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006, 6:27-33.
38. Horstmann S., Lucae S., Menke A., Hennings J.M., Ising M., Roeske D., et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
39. Hranilovic D., Stefulj J., Schwab S., Borrmann-Hassenbach M., Albus M., Jernej B., et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry 2004, 55:1090-1094.
40. Huezo-Diaz P., Uher R., Smith R., Rietschel M., Henigsberg N., Marusic A., et al. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry 2009, 195:30-38.
41. Huuhka K., Anttila S., Huuhka M., Leinonen E., Rontu R., Mattila K., et al. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257:31-35.
42. Illi A., Setala-Soikkeli E., Viikki M., Poutanen O., Huhtala H., Mononen N., et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
43. Illi A., Setala-Soikkeli E., Kampman O., Viikki M., Nuolivirta T., Poutanen O., et al. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res. 2010, 176:85-87.
44. Ito K., Yoshida K., Sato K., Takahashi H., Kamata M., Higuchi H., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002, 111:235-239.
45. Ji Y., Biernacka J., Snyder K., Drews M., Pelleymounter L.L., Colby C., et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J. 2012, 12:78-85.
46. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Miller A.L., Rogers G.R., et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol./Off.Sci.J. Coll. Int.Neuropsychopharmacol. (CINP). 2003, 6:339-346.
47. Kang R.H., Choi M.J., Paik J.W., Hahn S.W., Lee M.S. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int. J. Psychiatry Med. 2007, 37:315-329.
48. Kang R.H., Hahn S.W., Choi M.J., Lee M.S. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 2007, 56:1-5.
49. Kang R.H., Chang H.S., Wong M.L., Choi M.J., Park J.Y., Lee H.Y., et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J.psychopharmacol.(Oxf.) 2010, 24:1755-1763.
50. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
51. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
52. Kato M., Wakeno M., Okugawa G., Fukuda T., Azuma J., Kinoshita T., et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007, 56:167-171.
53. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:398-404.
54. Kato M., Wakeno M., Okugawa G., Fukuda T., Takekita Y., Hosoi Y., et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1041-1044.
55. Kato M., Fukuda T., Wakeno M., Okugawa G., Takekita Y., Watanabe S., et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:115-123.
56. Keers R., Bonvicini C., Scassellati C., Uher R., Placentino A., Giovannini C., et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. J.psychopharmacol. (Oxf.,) 2011, 25:867-874.
57. Kim D.K., Lim S.W., Lee S., Sohn S.E., Kim S., Hahn C.G., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000, 11:215-219.
58. Kim H., Lim S.W., Kim S., Kim J.W., Chang Y.H., Carroll B.J., et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006, 296:1609-1618.
59. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004, 9:442-473.
60. Kirchheiner J., Lorch R., Lebedeva E., Seeringer A., Roots I., Sasse J., et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9:841-846.
61. Kishi T., Fukuo Y., Yoshimura R., Okochi T., Kitajima T., Naitoh H., et al. Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. Hum. Psychopharmacol. 2010, 25:481-486.
62. Kishi T., Yoshimura R., Kitajima T., Okochi T., Okumura T., Tsunoka T., et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med. 2010, 12:237-242.
63. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25:218-227.
64. Kocabas N.A., Antonijevic I., Faghel C., Forray C., Kasper S., Lecrubier Y., et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int. Clin. Psychopharmacol. 2011, 26:1-10.
65. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 1997, 2:457-462.
66. Laika B., Leucht S., Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin. Chem. 2006, 52:893-895.
67. Lee H.J., Cha J.H., Ham B.J., Han C.S., Kim Y.K., Lee S.H., et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 2004, 4:29-33.
68. Lee S.H., Lee K.J., Lee H.J., Ham B.J., Ryu S.H., Lee M.S. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin. Neurosci. 2005, 59:140-145.
69. Lekman M., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry 2008, 63:1103-1110.
70. Lemonde S., Du L., Bakish D., Hrdina P., Albert P.R. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. neuropsychopharmacol./Off. Sci.J.Coll. Int. Neuropsychopharmacol. (CINP) 2004, 7:501-506.
71. Li D., He L. Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior. Mol. Psychiatry 2007, 12:47-54.
72. Lin P.Y., Tsai G. Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia. Schizophr. Res. 2004, 71:353-360.
73. Lin E., Chen P.S., Chang H.H., Gean P.W., Tsai H.C., Yang Y.K., et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1167-1172.
74. Lopez-Leon S., Janssens A.C., Gonzalez-Zuloeta Ladd A.M., Del-Favero J., Claes S.J., Oostra B.A., et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry 2008, 13:772-785.
75. Lucae S., Ising M., Horstmann S., Baune B.T., Arolt V., Muller-Myhsok B., et al. HTR2A gene variation is involved in antidepressant treatment response. Eur. Neuropsychopharmacol. 2010, 20:65-68.
76. Machado M., Iskedjian M., Ruiz I., Einarson T.R. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr. Med. Res. Opin. 2006, 22:1825-1837.
77. Maier W., Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 1):12-20.
78. Mandelli L., Mazza M., Martinotti G., Tavian D., Colombo E., Missaglia S., et al. Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. J.psychopharmacol. (Oxf.,) 2010, 24:1747-1754.
79. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78:804-814.
80. Menu P., Gressier F., Verstuyft C., Hardy P., Becquemont L., Corruble E. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 2010, 62:193-197.
81. Mihaljevic Peles A., Bozina N., Sagud M., Rojnic Kuzman M., Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1439-1444.
82. Min W., Li T., Ma X., Li Z., Yu T., Gao D., et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacol. 2009, 205:409-417.
83. Minov C., Baghai T.C., Schule C., Zwanzger P., Schwarz M.J., Zill P., et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci. Lett. 2001, 303:119-122.
84. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:341-351.
85. Neto F.L., Borges G., Torres-Sanchez S., Mico J.A., Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr. Neuropharmacol. 2011, 9:530-552.
86. Nikisch G., Eap C.B., Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol. Res. 2008, 58:344-347.
87. Noro M., Antonijevic I., Forray C., Kasper S., Kocabas N.A., Lecrubier Y., et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 2010, 25:228-231.
88. O'Brien F.E., Dinan T.G., Griffin B.T., Cryan J.F. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 2012, 165:289-312.
89. O'Leary J.C., Dharia S., Blair L.J., Brady S., Johnson A.G., Peters M., et al. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS One 2011, 6:e24840.
90. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 2007, 104:83-90.
91. Parsey R.V., Olvet D.M., Oquendo M.A., Huang Y.Y., Ogden R.T., Mann J.J. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006, 31:1745-1749.
92. Parsons M.J., D'Souza U.M., Arranz M.J., Kerwin R.W., Makoff A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 2004, 56:406-410.
93. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry 2009, 65:785-791.
94. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 2004, 9:879-889.
95. Peters E.J., Slager S.L., Jenkins G.D., Reinalda M.S., Garriock H.A., Shyn S.I., et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet. Genomics 2009, 19:1-10.
96. Porcelli S., Drago A., Fabbri C., Gibiino S., Calati R., Serretti A. Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci. 2011, 36:87-113.
97. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 2012, 22:239-258.
98. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002, 2:191-196.
99. Sarginson J.E., Lazzeroni L.C., Ryan H.S., Schatzberg A.F., Murphy G.M. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:554-560.
100. Sato K., Yoshida K., Takahashi H., Ito K., Kamata M., Higuchi H., et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46:136-140.
101. Serretti A., Franchini L., Gasperini M., Rampoldi R., Smeraldi E. Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatr. Scand. 1998, 98:443-450.
102. Serretti A., Zanardi R., Cusin C., Rossini D., Lorenzi C., Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 2001, 11:375-380.
103. Serretti A., Zanardi R., Rossini D., Cusin C., Lilli R., Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 2001, 6:586-592.
104. Serretti A., Lorenzi C., Cusin C., Zanardi R., Lattuada E., Rossini D., et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur. Neuropsychopharmacol. 2003, 13:117-122.
105. Serretti A., Cusin C., Rossini D., Artioli P., Dotoli D., Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 129B:36-40.
106. Serretti A., Artioli P., Lorenzi C., Pirovano A., Tubazio V., Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. neuropsychopharmacol./Off.Sci. J. Coll. Int.Neuropsychopharmacol. (CINP) 2004, 7:453-460.
107. Serretti A., Chiesa A., Calati R., Perna G., Bellodi L., De Ronchi D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int. Clin. Psychopharmacol. 2009, 24:1-18.
108. Singh A.B., Bousman C.A., Ng C.H., Byron K., Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl. psychiatry 2012, 2:e198.
109. Smith R.M., Papp A.C., Webb A., Ruble C.L., Munsie L.M., Nisenbaum L.K., et al. Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol. Psychiatry 2013, 73:546-554.
110. Spronk D., Arns M., Barnett K.J., Cooper N.J., Gordon E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J. Affect. Disord. 2011, 128:41-48.
111. Stein D.J., Daniels W.M., Savitz J., Harvey B.H. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr. 2008, 13:945-949.
112. Su N., Zhang L., Fei F., Hu H., Wang K., Hui H., et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 2011, 1415:119-126.
113. Szegedi A., Rujescu D., Tadic A., Muller M.J., Kohnen R., Stassen H.H., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5:49-53.
114. Tatro E.T., Everall I.P., Kaul M., Achim C.L. Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res. 2009, 1286:1-12.
115. Taylor W.D., McQuoid D.R., Ashley-Koch A., MacFall J.R., Bridgers J., Krishnan R.R., et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 2011, 11:146-154.
116. The International Schizophrenia C, Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
117. Touma C., Gassen N.C., Herrmann L., Cheung-Flynn J., Bull D.R., Ionescu I.A., et al. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry 2011, 70:928-936.
118. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
119. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 123B:19-22.
120. Tsai S.J., Hong C.J., Chen T.J., Yu Y.W. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:1097-1098.
121. Tsai S.J., Gau Y.T., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord. 2009, 113:183-187.
122. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009, 9:225-233.
123. Viikki M., Huuhka K., Leinonen E., Illi A., Setala-Soikkeli E., Huuhka M., et al. Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci. Lett. 2011, 501:20-24.
124. Villafuerte S.M., Vallabhaneni K., Sliwerska E., McMahon F.J., Young E.A., Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr. Genet. 2009, 19:281-291.
125. Wang H.C., Yeh T.L., Chang H.H., Gean P.W., Chi M.H., Yang Y.K., et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacol. 2011, 213:773-779.
126. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. Accessed on Dec 31 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
127. WHO DEPRESSION: A Global Public Health Concern. WHO paper written for the World Federation of Mental Health 2012, [Accessed on Dec 21 2012. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf].
128. Wilkie M.J., Smith D., Reid I.C., Day R.K., Matthews K., Wolf C.R., et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics 2007, 17:207-215.
129. Wilkie M.J., Smith G., Day R.K., Matthews K., Smith D., Blackwood D., et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009, 9:61-70.
130. Wu W.H., Huo S.J., Cheng C.Y., Hong C.J., Tsai S.J. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001, 44:172-175.
131. Xu Z., Zhang Z., Shi Y., Pu M., Yuan Y., Zhang X., et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J. Affect. Disord. 2011, 133:165-173.
132. Xu G., Lin K., Rao D., Dang Y., Ouyang H., Mai G., et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr. Genet. 2012, 22:214-215.
133. Xu Z., Zhang Z., Shi Y., Pu M., Yuan Y., Zhang X., et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J. psychopharmacol.(Oxf.,) 2012, 26:349-359.
134. Yoshida K., Naito S., Takahashi H., Sato K., Ito K., Kamata M., et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1279-1283.
135. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry 2004, 161:1575-1580.
136. Yoshida K., Higuchi H., Kamata M., Takahashi H., Inoue K., Suzuki T., et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. psychopharmacol. (Oxf.,) 2007, 21:650-656.
137. Yoshida K., Higuchi H., Takahashi H., Kamata M., Sato K., Inoue K., et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol. 2008, 23:121-128.
138. Yoshimura R., Kishi T., Suzuki A., Umene-Nakano W., Ikenouchi-Sugita A., Hori H., et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1022-1025.
139. Yu Y.W., Tsai S.J., Liou Y.J., Hong C.J., Chen T.J. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur. Neuropsychopharmacol. 2006, 16:498-503.
140. Yu W., Wulf A., Liu T., Khoury M.J., Gwinn M. Gene Prospector: an evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics 2008, 9:528.
141. Zhao X., Huang Y., Li J., Ma H., Jin Q., Wang Y., et al. Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 2012, 27:314-320.
142. Zhao X., Jin Q., Wu L., Huang Y., Li J., Zhu G. Sertraline (Zoloft) response in major depressive disorder is not associated with three 5-HT1A receptor gene polymorphisms (rs6295, rs10042486, or rs1364043) in Chinese-Han patients. Psychiatr. Genet. 2012, 22:261-262.
143. Zill P., Baghai T.C., Zwanzger P., Schule C., Minov C., Riedel M., et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000, 11:1893-1897.
144. Zobel A., Schuhmacher A., Jessen F., Hofels S., von Widdern O., Metten M., et al. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP). 2010, 13:649-660.
145. Zou Y.F., Wang Y., Liu P., Feng X.L., Wang B.Y., Zang T.H., et al. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum. Psychopharmacol. 2010, 25:145-152.
146. Zou Y.F., Wang Y., Liu P., Feng X.L., Wang B.Y., Zang T.H., et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010, 61:71-78.
147. Zou Y.F., Ye D.Q., Feng X.L., Su H., Pan F.M., Liao F.F. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol. 2010, 20:535-544.